STAR Protocols (Jun 2021)

An optimized protocol for patient-derived xenograft in humanized mice to evaluate the role of IL-34 in immunotherapeutic resistance

  • Nanumi Han,
  • Hye Yoon Jang,
  • Naoki Hama,
  • Takuto Kobayashi,
  • Ryo Otsuka,
  • Haruka Wada,
  • Ken-ichiro Seino

Journal volume & issue
Vol. 2, no. 2
p. 100460

Abstract

Read online

Summary: Previously, we identified a therapy-resistant role of IL-34 in an immune checkpoint blockade in murine models. To investigate whether a similar mechanism is applicable in human tumors as well, we used this protocol for the selection of IL-34-neutralizing antibody and transplanting human tumor tissue expressing both IL-34 and PD-L1 as a patient-derived xenograft in immunologically humanized mice. This model helps to determine the effect of IL-34 neutralization along with the immune checkpoint blockade in human tumors.For complete details on the use and execution of this protocol, please refer to Hama et al. (2020).

Keywords